This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Vital Farms (VITL) Declines More Than Market: Some Information for Investors
by Zacks Equity Research
Vital Farms (VITL) concluded the recent trading session at $34.77, signifying a -1.72% move from its prior day's close.
Analysts Estimate Vital Farms (VITL) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Vital Farms (VITL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Natural Foods Stocks Positioned for Success in 2025
by Sumit Singh
Companies like United Natural Foods, Sprouts Farmers and Beyond Meat are responding to the rising demand for organic and ethically sourced foods.
Vital Farms, Inc. (VITL) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Zacks.com users have recently been watching Vital Farms (VITL) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Why Vital Farms (VITL) Outpaced the Stock Market Today
by Zacks Equity Research
In the latest trading session, Vital Farms (VITL) closed at $35.71, marking a +0.85% move from the previous day.
Vital Farms (VITL) Stock Drops Despite Market Gains: Important Facts to Note
by Zacks Equity Research
Vital Farms (VITL) closed at $37.69 in the latest trading session, marking a -0.84% move from the prior day.
Why Vital Farms (VITL) Dipped More Than Broader Market Today
by Zacks Equity Research
Vital Farms (VITL) reachead $42.37 at the closing of the latest trading day, reflecting a -1.78% change compared to its last close.
Vital Farms (VITL) Exceeds Market Returns: Some Facts to Consider
by Zacks Equity Research
In the latest trading session, Vital Farms (VITL) closed at $44.39, marking a +1.05% move from the previous day.
Is It Worth Investing in Vital Farms (VITL) Based on Wall Street's Bullish Views?
by Zacks Equity Research
The average brokerage recommendation (ABR) for Vital Farms (VITL) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Vital Farms (VITL) Advances While Market Declines: Some Information for Investors
by Zacks Equity Research
Vital Farms (VITL) closed at $43.14 in the latest trading session, marking a +1.1% move from the prior day.
Vital Farms (VITL) Advances While Market Declines: Some Information for Investors
by Zacks Equity Research
In the closing of the recent trading day, Vital Farms (VITL) stood at $40.13, denoting a +1.9% change from the preceding trading day.
STZ Q3 Earnings Miss, Sales Dip Y/Y on Weak Wine & Spirits Business
by Zacks Equity Research
Constellation Brands posts a y/y sales decline in third-quarter fiscal 2025 due to softness in the wine and spirits segment.
Newell's Innovations & Other Strategies Encouraging: Apt to Hold
by Zacks Equity Research
NWL's strategic endeavors, including organizational realignment and cost-saving efforts, bode well.
Clorox Stock Rises 23% in Six Months: Is it Time to Buy or Avoid?
by Zacks Equity Research
CLX benefits from robust pricing and cost-saving initiatives. The company's IGNITE strategy also bodes well.
Dutch Bros Rolls Out Cereal Beverages, On Track With Growth Efforts
by Zacks Equity Research
BROS introduces two cereal-inspired beverages, including the Cinnamon Swirl and Marshmallow Dream.
FMX Divests Plastics Solutions to AMMI, Progresses Well on Forward Plan
by Zacks Equity Research
Fomento progresses smoothly on its Forward plan. The company divests its plastics solutions operations to AMMI.
Is Vital Farms (VITL) a Buy as Wall Street Analysts Look Optimistic?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in Vital Farms (VITL). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
Keurig Dr Pepper Benefits From Brand Strength, Pricing & Innovation
by Zacks Equity Research
KDP gains from innovation and the solid performance in its Refreshment Beverages segment.
Newell Rises 61.7% in a Year: Time to Buy, Sell or Hold the Stock?
by Zacks Equity Research
NWL's strategic endeavors, including investments in innovation and brand-building efforts, bode well.
CL's Pricing & Productivity Efforts Seem Encouraging: Apt to Hold?
by Zacks Equity Research
Colgate benefits from robust pricing and productivity initiatives. The company's innovation strategy also bodes well.
Boston Beer Amends Production Agreement With Rauch, Revises 2024 View
by Zacks Equity Research
SAM makes amendments to its existing production agreement with Rauch. It updates guidance for 2024.
Clorox Gains 20.5% in Past Six Months: Time to Buy or Hold the Stock?
by Zacks Equity Research
CLX benefits from robust pricing and cost-saving initiatives. The company's IGNITE strategy also bodes well.
Boston Beer Gains From Brand Strength & Innovation: Apt to Hold?
by Zacks Equity Research
SAM benefits from strong price realization, innovation and procurement savings.
Tilray Brands Introduces Herb & Bloom Non-Alcoholic Beverage
by Zacks Equity Research
TLRY's innovation efforts are quite on track, with the launch of Herb & Bloom, which is a line of cocktail-inspired ready-to-drink, alcohol-free effervescent beverages.
MDLZ Approves a $9-B Repurchase Plan: Here's What You Should Know
by Zacks Equity Research
Mondelez authorizes the latest share repurchase authorization of up to $9 billion of its Class A common stock.